Mediaboss Marketing

First and total coronary revascularization event reductions of 34% and 36%, respectively, shown with VASCEPA in prespecified tertiary endpoint analyses

Results of prespecified tertiary endpoint analyses consistent across different types of coronary revascularization procedures, including urgent, emergent, and elective interventions

Percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) reduced by 32% and 39%, respectively, in post hoc exploratory analyses

DUBLIN, Ireland and BRIDGEWATER, N.J., May 14, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that data from the REDUCE-IT study presented by Benjamin E. Peterson, M.D., Brigham and Womens Hospital Heart & Vascular Center and Harvard Medical School, at the Society for Cardiovascular Angiography & Interventions 2020 Scientific Sessions, showed that administration of 4 g/day of VASCEPA (icosapent ethyl) resulted in a significant 34% reduction in first coronary revascularizations versus placebo (p<0.0001). Similar reductions of 36% were observed in total, or first and subsequent, revascularizations (p<0.0001).

These findings from the REDUCE-IT study put in further context the broad-reaching impact of icosapent ethyl on reducing the burden of cardiovascular disease for patients, commented Dr. Deepak L. Bhatt, M.D., M.P.H., Executive Director of Interventional Cardiovascular Programs at Brigham and Womens Hospital Heart & Vascular Center and Professor of Medicine at Harvard Medical School, and senior author of the REDUCE-IT REVASC analyses. To the best of our knowledge, this is the first non-LDL cholesterol intervention in a major randomized trial in which analyses support that statin-treated patients underwent fewer CABG surgeries, further highlighting the substantial impact of icosapent ethyl on the underlying atherothrombotic burden in this at-risk population.

Coronary revascularization procedures are invasive, carry multiple risks, and can have significant direct and indirect costs. Patients with elevated triglycerides despite statin therapy have increased risk for ischemic events, including coronary revascularizations. These procedures, whether pre-scheduled or performed in an emergency, oftentimes result in additional time spent in a healthcare setting.

The analyses from the REDUCE-IT study included several types of coronary revascularization events in statin-treated patients with persistent elevated triglycerides (135-499 mg/dL), who also had either cardiovascular disease or diabetes and additional cardiovascular risk factors. Prespecified tertiary endpoint analyses showed that times to first revascularization events were significantly reduced by VASCEPA versus placebo across subtypes of intervention, including urgent, emergent, and elective revascularizations, which were reduced by 34% (p<0.0001), 38% (p=0.02), and 32% (p<0.0001), respectively. In post hoc analyses, VASCEPA significantly reduced percutaneous coronary intervention (PCI) by 32% (p<0.0001) and coronary artery bypass grafting (CABG) by 39% relative to placebo (p=0.0005).

REDUCE-IT was not specifically powered to examine individual cardiovascular endpoints, therefore p-values presented for these revascularization analyses are nominal and exploratory with no adjustment for multiple comparisons. In addition, coronary revascularization as an endpoint can sometimes be considered subjective; however, these endpoints were adjudicated by an independent, blinded clinical endpoint committee. Results from the total coronary revascularization events analyses are consistent across the various recurrent event statistical models and are also consistent with the first coronary revascularization events results. Together, the REDUCE-IT first and total coronary revascularization events results support the robustness and consistency of the clinical benefit of VASCEPA therapy in reducing coronary revascularization.

Revascularization procedures significantly impact the healthcare system, said Steven Ketchum, Ph.D., senior vice president and president, research & development and chief scientific officer, Amarin. These data reflect new findings consistent with FDA-approved findings that continue to support that the use of VASCEPA has the potential to transform cardiovascular care in appropriate high-risk patients.

Slides from the presentation are available at http://www.scai.org/SCAI2020

About Amarin

Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarins lead product, VASCEPA (icosapent ethyl), is available by prescription in the United States, Canada, Lebanon and the United Arab Emirates. Amarin, together with its commercial partners in select geographies, is pursuing additional regulatory approvals for VASCEPA in China, the European Union and the Middle East. For more information about Amarin, visit http://www.amarincorp.com.

About Cardiovascular Risk

The number of deaths in the United States attributed to cardiovascular disease continues to rise.1,2 There are 605,000 new and 200,000 recurrent heart attacks per year (approximately 1 every 40 seconds), in the United States. Stroke rates are similar, accounting for 1 of every 19 U.S. deaths (approximately 1 every 40 seconds).3

Controlling bad cholesterol, also known as LDL-C, is one way to reduce a patients risk for cardiovascular events, such as heart attack, stroke or death. However, even with the achievement of target LDL-C levels, millions of patients still have significant and persistent risk of cardiovascular events, especially those patients with elevated triglycerides. Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35% but that still leaves a 65-75% risk remaining.4 People with elevated triglycerides have 35% more cardiovascular events compared to people with normal (in range) triglycerides taking statins.5,6,7

About REDUCE-IT

REDUCE-IT was a global cardiovascular outcomes study designed to evaluate the effect of VASCEPA in adult patients with LDL-C controlled to between 41-100 mg/dL (median baseline 75 mg/dL) by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides between 135-499 mg/dL (median baseline 216 mg/dL) and either established cardiovascular disease (secondary prevention cohort) or diabetes mellitus and at least one other cardiovascular risk factor (primary prevention cohort).

REDUCE-IT, conducted over seven years and completed in 2018, followed 8,179 patients at over 400 clinical sites in 11 countries with the largest number of sites located within the United States. REDUCE-IT was conducted based on a special protocol assessment agreement with FDA. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology.8The primary results of REDUCE-IT were published in The New England Journal of Medicine in November 2018.9The total events results of REDUCE-IT were published in the Journal of the American College of Cardiology in March 2019.10 These and other publications can be found in the R&D section on the companys website at http://www.amarincorp.com.

About VASCEPA (icosapent ethyl) Capsules

VASCEPA (icosapent ethyl) capsules are the first-and-only prescription treatment approved by the FDA comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was initially launched in the United States in 2013 based on the drugs initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed over eight million times. VASCEPA is covered by most major medical insurance plans. The new, cardiovascular risk indication for VASCEPA was approved by the FDA in December 2019.

Indications and Limitation of Use

VASCEPA is indicated:

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

Important Safety Information

Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies section of the prescribing information for VASCEPA, as set forth below:

Effect of VASCEPA on Time to First Occurrence of Cardiovascular Events in Patients with Elevated Triglyceride levels and Other Risk Factors for Cardiovascular Disease in REDUCE-IT

n (%)

n (%)

(17.2)

(22.0)

(0.68, 0.83)

(11.2)

(14.8)

(0.65, 0.83)

(6.1)

(8.7)

(0.58, 0.81)

(5.3)

(7.8)

(0.55, 0.78)

(4.3)

(5.2)

(0.66, 0.98)

(2.6)

(3.8)

(0.53, 0.87)

(2.4)

(3.3)

(0.55, 0.93)

[2] Determined to be caused by myocardial ischemia by invasive/non-invasive testing and requiring emergent hospitalization.

FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT http://WWW.VASCEPA.COM.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the potential impact of VASCEPA in various clinical uses. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated generally with research and development and clinical trials such as further clinical evaluations failing to confirm earlier findings. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Amarins forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate.

Availability of Other Information About Amarin

Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarins investor relations website and may include social media channels. The contents of Amarins website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information

Investor and Media Inquiries:Elisabeth SchwartzInvestor RelationsAmarin Corporation plcIn U.S.: +1 (908) 719-1315investor.relations@amarincorp.com (investor inquiries)PR@amarincorp.com (media inquiries)

Lee M. SternSolebury TroutIn U.S.: +1 (646) 378-2992lstern@soleburytrout.com

_____________________________1 American Heart Association. Heart Disease and Stroke Statistics 2019 Update: A Report from the American Heart Association. Published January 31, 2019.2 American Heart Association / American Stroke Association. 2017. Cardiovascular disease: A costly burden for America projections through 2035.3 American Heart Association: Heart Disease and Stroke Statistics -- 2019 At-a-Glance.4 Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343.5 Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016;118:138-145.6 Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740.7 Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease - New insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547-563.8 Bhatt DL, Steg PG, Brinton E, et al., on behalf of the REDUCE-IT Investigators. Rationale and Design of REDUCEIT: Reduction of Cardiovascular Events with Icosapent EthylIntervention Trial. Clin Cardiol. 2017;40:138-148.9 Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22.10 Bhatt DL, Steg PG, Miller M, et al., on behalf of the REDUCE-IT Investigators. Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles. J Am Coll Cardiol. 2019;74:1159-1161.

Go here to read the rest:
VASCEPA (icosapent ethyl) Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardiac Bypass Surgery, in...

Pandemic has tilted the scale in favor of domestic travel, experts say

Restrictions on businesses of all kinds as a result of the COVID-19 outbreak left the majority no choice but to shut down, at least temporarily. The tourism and hospitality sector has been among the hardest hit.

More than 75 million hospitality and tourism employees worldwide are expected to lose their jobs in 2020 as a result of the pandemic, according to Statista.com. Furthermore, the industrys revenue is projected to fall by about 35% over the previous year, with Europe being the worst affected.

More than 4.5 million tourists visited Israel in 2019, injecting over $5.5 billion into the economy.

In the first two months of 2020, 3.3 million stays were registered in Israels hotels. Over 200,000 workers were employed in the industry, accounting for 2.5% to 3% of gross domestic product.

In the Red Sea city of Eilat, whose economy is highly dependent on tourism, the unemployment rate has soared past 70%, to the highest level in Israel.

Following six weeks at a virtual standstill, the hospitality and tourism industry is preparing for a gradual return to business.

The cabinet has tentatively approved the reopening of guesthouses and ground-level hotel rooms starting this coming Sunday, provided that the national infection rate does not rise by the scheduled opening date. However, pools, hot tubs and dining rooms will remain closed. According to experts, a return to the pre-COVID-19 occupancy level may take between 18 and 48 months.

Inbound air travel, thus far limited to a handful of flights from Newark, Moscow and Addis Ababa, and assorted rescue flights from other cities, will resume from next month, despite the continued barring of entry to all non-Israelis. Israelis returning from abroad are required to enter 14 days of isolation in government-supplied hotels.

One after the other, foreign airlines have announced the resumption of flights to Tel Aviv. Wizz Air, British Airways, Delta and Air Canada flights can be booked online for next month. As for new outbound air travel options, Israelis will have to wait until June. Then Air India may start Tel Aviv-Delhi flights and Alitalia will offer Tel Aviv-Rome.

While the airline industry is preparing itself for a return to business as usual in the very near future, not all travelers may be ready to book their next flight quite so soon. Experts believe the recovery of the airline industry is likely to be gradual. An even slower recovery is seen as possible but less likely, depending on how long national economies are shut down.

A study conducted on the behalf of the International Air Transport Association (IATA) shows that 60% of travelers are likely to return to flying within one to two months of containment of the COVID-19 pandemic. However, as many as 40% of respondents reported that they would put off travel for at least six months.

In the same study, 69% reported that they were likely to defer a return to travel until their financial situation stabilized. This is not surprising given that hundreds of millions around the world either lost their jobs or are at risk of losing them due to the coronavirus pandemic. In the US alone, more than 24 million people lost their jobs. In Israel, over a million employees were sent home, either laid off or furloughed without pay.

A breakdown of international and domestic travel prospects shows an interesting outlook for the hospitality and tourism industry. Experts believe that for the foreseeable future, domestic travel will be more dominant than previously.

Initially travel is likely to be domestic rather than international, Omry Livtak, chief operating officer and co-founder of Hotelmize, tells The Media Line.

Drive holidays such as regional travel within the US and Europe is a likely scenario, Andy Owen-Jones, CEO at Bd4travel, tells The Media Line.

There are several possible reasons for this. There is concern over mandatory quarantine upon return to ones home country. Another possible reason is the perceived risk associated with traveling abroad.

The experts views are supported by recent research data. An international study this writer conducted with his colleagues suggests that over 50% of individuals were likely to travel domestically in the next six months. The number of those likely to travel domestically in the next 12 months is considerably higher, with about 70% saying they would do so.

As for international travel, roughly 30% of respondents reported they were likely to travel abroad in the next six months. However, over 50% reported they were likely to travel abroad in the next 12 months.

Although a majority of tourists may be deterred from traveling abroad in the next 12 months, tourism-dependent economies may be able to compensate for at least some of the lost income with the help of domestic tourists.

People will not give up on their vacations, Livtak says.

As for Israelis, The fact that Tel Aviv is expensive will not deter Israelis from booking rooms at hotels located in the city, Livtak says. The city has a lot to offer. Israelis are likely to flock to the city as previously popular destinations such as Greece and Cyprus along with all other foreign destinations no longer top their list of holiday destinations.

Which destinations are likely to be travelers favorites once they resume international travel? A study this writer and his colleagues are conducting shows that Europe and the US top the list. Despite reports of racism toward ethnic Chinese around the world, including in the US, Canada and the UK, two-thirds of respondents stated a willingness to visit China in the future, with over 50% saying they would travel there mainly for vacations.

Read the rest here:
The Future of Travel: Where Will People Fly After COVID-19 Is Brought Under Control? - The Media Line

Even if it sometimes feels impossible, you can control anxiety attacks when you understand your triggers and what calms you.

An anxiety attack can be a frightening experience. You may feel like you can't breathe, that your heart is racing too quickly, your head is spinning and you can't control your thoughts. Anxiety attacks are often accompanied by or triggered by feelings of doom or fear, and it can feel like the anxiety will never end.

Even when it seems like you can't stop the spiral, you can: With the right tactics, you can learn how to control and prevent anxiety attacks. It's much more complex, however, than the "don't panic" and "just breathe" statements often given as advice for managing anxiety, licensed psychotherapistHaley Neidichsays.

Note that you needn't be diagnosed with anxiety or another mental health condition to have an anxiety attack: Anyone can experience an anxiety attack even in the absence of a psychiatric diagnosis, and everyone can benefit from knowing how to control one in the case one occurs.

Also note that there's a difference between an anxiety attack and a panic attack. A panic attack is clearly defined by the Diagnostic and Statistical Manual of Psychiatric Disorders, while an anxiety attack is not.

One of the biggest differences between the two is that panic attacks often occur without warning and may be triggered by an external fear, such as a phobia you come into contact with, but panic attacks can occur without any triggers. Anxiety attacks, on the other hand, often build over time and are often triggered by an internal fear or feeling of doom, such as what might happen when thinking about the coronavirus pandemic.

Now playing: Watch this: Ways to stay calm in a crisis

1:31

The lack of diagnostic criteria doesn't make anxiety attacks invalid; it just means that symptoms are more open to interpretation and that there's an opportunity to uncover anxiety-inducing triggers.

With that, here's how to tell if you're having an anxiety attack and how to stop or control it.

Read more: How to calm anxiety in social settings

As an anxiety attack approaches or builds, you may feel a lack of control accompanied by symptoms like a racing heartbeat and unstoppable thoughts.

If you haven't had an anxiety attack before, you may not even know what to look out for. Even if you do experience anxiety attacks regularly, the signs leading up to an anxiety attack can change, leaving you bewildered if one time feels different than the last.

"While many people can easily identify their triggers and early warning signs, it is something that can take time and support," Neidich explains. "Some people will experience anxiety attacks that seem to come out of nowhere and they may require professional support from a psychotherapist in order to help them identify the more subtle and underlying issues that are contributing."

That said, and although everyone experiences anxiety attacks differently, Neidich says a few omnipresent signs show up in most people.

"The most common early symptom is anxious thinking, particularly thinking rooted in 'what ifs' which typically lead people down a dark mental path," Neidich says. "This can happen slowly or quickly, depending on the external environment and vulnerability factors of an individual."

Racing thoughts and physiological symptoms like a racing heart, difficulty breathing and gastrointestinal disturbance are all telltale signs of an anxiety attack or severe anxiety in general, Neidich says.

"Anxiety attacks can be a terrifying experience as people often report feeling as if they are dying or having a heart attack during the episode," she says. "For this reason, many people who have experienced an anxiety attack will develop a fear of having another one, only compounding their underlying anxiety."

That's all the more reason that recognizing the early symptoms of an anxiety attack are key in preventing and controlling them, Neidich reiterates.

Read more: 5 online therapy services to help with depression, anxiety and stress

To control anxiety attacks, you need to understand your triggers as well as what techniques can calm you down.

It can be difficult to stop an anxiety attack entirely once it's started, but you can take some steps to control anxiety attacks, reduce the severity of symptoms and decrease their frequency. Neidich shares five tips for controlling and coping with anxiety attacks.

"Distraction is the No. 1 tool for managing an anxiety attack once it has gotten started," Neidich says. She adds that paying too much attention to your body -- like trying to breathe deeply, as is often recommended -- can make your symptoms worse.

Instead, Neidich says, "Once you've identified that an anxiety attack has started, it's time to distract yourself while you wait for it to pass. Put on a funny movie, grab a coloring book, go for a walk, listen to a podcast, put on your anxiety-soothing playlist or call a friend and tell them you need to talk about something else."

As you discover tools that work for you, keep a running list in the notepad on your phone, so if you find yourself unsure of what to do, you can simply scroll through that list. As for finding distraction tools, Neidich says that just about anything will work as long as it doesn't make your anxiety worse.

"Social media makes many people's anxiety worse, yet I just had someone mention to me that watching dance videos on TikTok helped them to get through an anxiety attack," Neidich says as an example. "We are all individual and need to take the time to figure out what will improve our symptoms."

Listening to a playlist of calming or fun songs can help reduce anxiety.

Aftercare is how you soothe yourself once the anxiety attack is abating, Neidich says. This can include tactics similar to distractions, such as taking a walk, journaling or calling someone. If you choose to call someone, Neidich says make sure it's someone who "knows not to ask you why you had the anxiety attack" (see tip No. 4 for more on that).

"Once the peak of the anxiety attack has occured," Neidich says, "using grounding techniques to feel more present in your body is a big part of aftercare."

Try these grounding techniques Neidich recommends:

Neidich also offers a visualization exercise to help: Once your anxiety starts to dissipate, visualize yourself as a tree with roots growing into the ground as "a powerful way to begin to ground."

Use grounding visualizations, such as picturing yourself as a tree or other plant, to center yourself during an anxiety attack.

The prevailing sentiment that meditation and deep breathing can or should be used to stop an anxiety attack can actually be harmful, Neidich says.

"Meditation and deep breathing are typically poor skills to use once an anxiety attack has already started and can, in fact, make things much worse," she says. "Instead, people who have anxiety should be meditating twice per day in order to decrease their overall anxiety so that they can more effectively identify worsening anxiety symptoms."

Neidich notes that it's common for people to say "I know I should meditate" and then ignore meditation as a potential tool -- but "daily meditation has the potential impact of stopping anxiety attacks completely and the recommendation should be taken very seriously," she says.

It's true,meditation is known to reduce stress, anxiety, depression and emotional pain, as well as build resilience, or your ability to bounce back from stressful or painful situations.

Meditating is a great preventative tactic for anxiety. If you have trouble meditating on your own, try an app like Calm on the Apple Watch.

A network of support people is essential to managing anxiety, Neidich says, but those support people must be effective in helping you cope -- that is, they should make you feel better, not worse.

Lean on people who can offer you the kind of support you personally need, like physical touch or an ear to listen to how you feel. Avoid anyone who asks you why you had an anxiety attack. After an anxiety attack or on the fringes of one, it's important to not talk about the cause behind it, Neidich says, pointing back to distraction techniques.

It's important to be clear on what you need from your loved ones in regard to anxiety, Neidich says -- it's a "huge part of a comprehensive anxiety-management plan."

"Be sure to talk ahead of time about what language is and is not helpful," Neidich says, noting that it's not someone else's responsibility to help you with your anxiety attack, but it is your responsibility to communicate your needs.

Read more: 5 life hacks for relieving anxiety

The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.

Originally posted here:
How to stop and prevent an anxiety attack - CNET

When President Donald Trump held his nightly White House press briefing on the coronavirus pandemic on Friday, April 24, a White House staffer was determined to micromanage which journalists would be seated where and Washington Post media critic Erik Wemble offers a scathing analysis in a video posted on Twitter and YouTube, explaining why the staffers actions were so egregious.

The White House is invoking the Secret Service and using cheap intimidation tactics to scare reporters into other seats, Wemple asserts in the video. And the Post media critic goes on to say, Theyre using these seats to accomplish a change in tone in the briefing room. The president doesnt want to answer or even face the sort of questions that CNN and other outlets are asking in that briefing room. It doesnt matter where you put the reporters; those questions have to be answered.

We got a bit of footage of the White House trying to reassign seats before Friday nights briefing: https://t.co/RnhDLOrflJ

ErikWemple (@ErikWemple) April 28, 2020

In video footage taken before the press conference got underway, Wemple explains, Katie Price (a White House official) is seen asking Washington Blade reporter Chris Johnson to move from the back of the White House briefing room to the front row where CNNs Kaitlan Collins had planned to sit.

Wemple, in the video, asserts, Its not Prices role or job to tell reporters where to sit. Its not even the presidents job or the chief of staffs job. That job falls to the White House Correspondents Association.

In the video, Wemple explains that the WHCA was founded in 1914 when Democrat Woodrow Wilson was president and one of things it is designed to do is make sure that reporters who are likely to ask tough questions arent marginalized. In other words, someone like Collins, theoretically, should be seated near the front because she is more likely to ask tough questions. The WHCA, as Wemple lays out in the video, is designed to encourage reporters to act as watchdogs which is what they are supposed to do in a democratic republic.

Watch the video below:

then let us make a small request. AlterNets journalists work tirelessly to counter the traditional corporate media narrative. Were here seven days a week, 365 days a year. And were proud to say that weve been bringing you the real, unfiltered news for 20 yearslonger than any other progressive news site on the Internet.

Its through the generosity of our supporters that were able to share with you all the underreported news you need to know. Independent journalism is increasingly imperiled; ads alone cant pay our bills. AlterNet counts on readers like you to support our coverage. Did you enjoy content from David Cay Johnston, Common Dreams, Raw Story and Robert Reich? Opinion from Salon and Jim Hightower? Analysis by The Conversation? Then join the hundreds of readers who have supported AlterNet this year.

Every reader contribution, whatever the amount, makes a tremendous difference. Help ensure AlterNet remains independent long into the future. Support progressive journalism with a one-time contribution to AlterNet, or click here to become a subscriber. Thank you. Click here to donate by check.

The rest is here:
Media critic breaks down cheap intimidation tactics used by Trumps White House to control press briefing room - AlterNet

Bauer Media, publisher of dozens of magazines including Australian Womens Weekly and Harpers Bazaar, is suspending the printing of certain titles and laying off 140 staff as coronavirus hits the advertising industry.

The announcement came just hours after Bauer title TV Week cancelled the TV Week Logies, which were originally to be held on the Gold Coast on 28 June.

The German-owned media giant refused to say which magazines would not be published but indicated some may never return to print.

However, sources say the staff of fashion magazines Harpers Bazaar and Elle and gossip weeklies OK! and NW have been stood down so they are likely to be among the titles affected.

The affected brands digital assets will continue to operate, Bauer said in a statement. The decision to resume print publication will be made once the trading environment improves.

Bauer Medias planned acquisition of Seven West Medias Pacific Magazines, which publishes Better Homes & Gardens, New Idea and Marie Claire, is expected to be completed on Friday despite speculation Bauer may have wanted to pull out.

Announced in October 2019, the $40m merger has been delayed for several weeks but Seven has told the Australian Securities Exchange the deal will now complete on 1 May.

Bauer staff were told by the Australian chief executive, Brendon Hill, on Wednesday that a restructure of the company meant that 70 people were to be made redundant and another 70 stood down.

These are unprecedented times, Hill said. The Covid-19 crisis and the strict measures being taken to control it are having a profound impact on the Australian economy and any business that operates in it.

This has led to a sharp decrease in advertising revenues in Australia over the short term and we have had to reshape our organisation accordingly.

The company blamed the impact of the coronavirus in Australia on advertising revenue but the magazine industry has been scaling back for years due to the digital revolution.

Many Australia titles have closed in the past few years, including Cleo, Top Gear, Zoo, Madison, Grazia, Burkes Backyard, BBC Good Food, FHM and Cosmopolitan.

Earlier this month the company closed New Zealand Womans Weekly and pulled its business out of the country completely.

Since Kerry Packers ACP Magazines was sold by Nine Entertainment for $500m in 2012, several titles have had their editorial teams merged and others closed entirely.

Mens magazine the Picture and the 69-year-old People magazine will close at the end of the year, ending decades of printed weeklies featuring topless models and readers sex stories, after they were banned from sale at service stations.

The TV Week Logies, the annual awards night for the television industry, would be held next year, said the Bauer Media Group publisher, Fiona Connolly.

All parties agree the most positive outcome is to not hold the TV Week Logies, including public voting, in 2020 but to stage an even bigger event on the Gold Coast in 2021, she said.

The TV Week Logies is loved because it is a live event, with viewers at home enjoying seeing the red-carpet glamour and the entertainment community coming together to celebrate the television industry.

Link:
Bauer Media suspends printing of 'certain' magazines and lays off 140 staff amid coronavirus fallout - The Guardian